Poor
Needs Revision
Patient Risk:
Moderate
Summary
The response correctly recognizes that most expired-product, oral-formulation, and expiration-related claims are absent from the supplied label. However, it materially misrepresents the supplied label by attributing abrupt-discontinuation warnings, contraindications, multiple warnings and precautions, pregnancy information, pediatric information, and overdose information to sections that were not provided.
Category Scores
Accurate Statements
The response states that the supplied label does not establish safety or potency after expiration for tablets, extended-release capsules, or other oral formulations.
The supplied label concerns metoprolol tartrate injection and does not discuss expired products, tablets, extended-release capsules, or post-expiration potency.
The response identifies that the supplied label is for metoprolol tartrate injection indicated for acute myocardial infarction in hemodynamically stable patients.
Section 1 identifies this indication.
The response notes that storage requirements are relevant to the supplied product.
Section 16 specifies storage at 20°C to 25°C, not freezing, and protection from light and heat.
The response notes that the label supports monitoring and management of bradycardia.
Sections 2 and 5.1 require monitoring of blood pressure, heart rate, and electrocardiogram or heart rate and rhythm, and state that severe bradycardia warrants dose reduction or discontinuation.
The response states that the label advises contacting a physician if difficulty breathing occurs.
Section 17 provides this patient counseling instruction.
Unsupported Statements
The label warns that abrupt cessation of chronic beta-blocker therapy may exacerbate angina and precipitate myocardial infarction, and that this is supported by section 5.1.
The supplied section 5.1 discusses bradycardia, sinus pause, heart block, cardiac arrest, monitoring, and dose reduction or discontinuation for severe bradycardia. It does not discuss abrupt cessation, angina, or myocardial infarction after withdrawal.
The supplied label contains contraindications in section 4, including severe bradycardia, greater-than-first-degree heart block, cardiogenic shock, decompensated heart failure, sick sinus syndrome, and significant hypotension.
Section 4 is not included in the supplied label sections, so these contraindications cannot be attributed to the available prescribing information.
The supplied label contains warnings in sections 5.3 through 5.10 concerning bronchospastic disease, pheochromocytoma, peripheral vascular disease, calcium-channel blocker interactions, masking of hypoglycemia or thyrotoxicosis, and hepatic impairment.
Those sections are not provided. The available warnings contain only sections 5.1 Bradycardia and 5.2 Heart Failure.
The response identifies pregnancy information in section 8.1 and pediatric-use information in section 8.4 as omitted FDA-label domains.
Sections 8.1 and 8.4 are not included in the supplied label.
The response identifies overdose information in section 10 as an omitted label domain.
Section 10 is not included in the supplied label.
The response characterizes the omitted domains as dangerous omissions from the original expired-metoprolol response.
The original response addressed expired metoprolol and included several safety-related statements. The supplied label does not provide the cited additional sections, and the response did not need to address every unrelated label domain to answer the expired-product question.
Contradictions
High
AI Statement
The response classifies the abrupt-discontinuation claim as supported by section 5.1.
Label Reference
Supplied section 5.1 addresses bradycardia, conduction disorders, monitoring, and dose reduction or discontinuation for severe bradycardia; it does not support abrupt-discontinuation warnings.
Important Omissions
The response should have explicitly limited its assessment to the sections actually supplied and stated that sections 4, 5.3-5.10, 8.1, 8.4, and 10 were unavailable rather than treating their contents as established by the provided label.
Importance:
High
The response should have noted the supplied label's actual administration details: three 5-mg intravenous boluses at approximately 2-minute intervals after hemodynamic stabilization, with monitoring of blood pressure, heart rate, and electrocardiogram, followed by transition to an oral formulation.
Importance:
Moderate
The response should have distinguished the label-supported warning about worsening cardiac failure in section 5.2 from unsupported claims about expired-product potency or withdrawal effects.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response is an audit rather than direct treatment advice, but its unsupported attribution of contraindications and warnings to the supplied label could undermine confidence in the evaluation and cause users to rely on information not present in the provided prescribing information. The incorrect claim that abrupt discontinuation is supported by section 5.1 is a material labeling error.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Revision
Primary Issue
The response hallucinates or imports content from unavailable label sections and incorrectly states that section 5.1 supports abrupt-discontinuation warnings.
Suggested Improvement
Restrict the evaluation to the supplied sections, remove unsupported references to sections 4, 5.3-5.10, 8.1, 8.4, and 10, and classify the abrupt-discontinuation claims as unsupported by the available label.